# | Title | Journal | Year | Citations |
---|
1 | 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer | Journal of Nuclear Medicine | 2019 | 874 |
2 | 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine | 2016 | 741 |
3 | Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein | Journal of Nuclear Medicine | 2018 | 522 |
4 | PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 | Journal of Nuclear Medicine | 2016 | 475 |
5 | 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers | Journal of Nuclear Medicine | 2019 | 468 |
6 | Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours | European Journal of Nuclear Medicine and Molecular Imaging | 2007 | 467 |
7 | A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts | Journal of Nuclear Medicine | 2018 | 453 |
8 | Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer | Journal of Nuclear Medicine | 2015 | 451 |
9 | Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 425 |
10 | F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 421 |
11 | Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy | Nature Medicine | 2012 | 414 |
12 | Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding | Journal of Nuclear Medicine | 2017 | 367 |
13 | The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions | Journal of Nuclear Medicine | 2015 | 332 |
14 | Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control | Journal of Nuclear Medicine | 2018 | 322 |
15 | Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy | European Journal of Nuclear Medicine and Molecular Imaging | 2014 | 319 |
16 | 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience | European Journal of Nuclear Medicine and Molecular Imaging | 2014 | 316 |
17 | Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience | European Journal of Nuclear Medicine and Molecular Imaging | 2014 | 290 |
18 | [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH | European Journal of Nuclear Medicine and Molecular Imaging | 2012 | 284 |
19 | Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention | Journal of Nuclear Medicine | 2019 | 281 |
20 | An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth | Current Radiopharmaceuticals | 2018 | 248 |
21 | Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy | Journal of Nuclear Medicine | 2019 | 238 |
22 | Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 234 |
23 | Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor | Journal of Hepatology | 2014 | 217 |
24 | Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction | Journal of Virology | 2010 | 201 |
25 | The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer | Journal of Nuclear Medicine | 2016 | 200 |
26 | 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients | European Journal of Nuclear Medicine and Molecular Imaging | 2016 | 194 |
27 | E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET | European Journal of Nuclear Medicine and Molecular Imaging | 2021 | 188 |
28 | Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging | Journal of Nuclear Medicine | 2017 | 186 |
29 | The Pharmacokinetics of Cell-Penetrating Peptides | Molecular Pharmaceutics | 2010 | 176 |
30 | Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models | Journal of Nuclear Medicine | 2020 | 176 |
31 | SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors | Molecular Imaging and Biology | 2015 | 172 |
32 | 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience | Journal of Nuclear Medicine | 2017 | 166 |
33 | PSMA Ligands for PET Imaging of Prostate Cancer | Journal of Nuclear Medicine | 2017 | 165 |
34 | Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy | Journal of Nuclear Medicine | 2017 | 163 |
35 | FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients | Journal of Nuclear Medicine | 2021 | 163 |
36 | New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy | Clinical Cancer Research | 2016 | 155 |
37 | Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors | Journal of Medicinal Chemistry | 2016 | 150 |
38 | Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2016 | 148 |
39 | Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing | European Journal of Nuclear Medicine and Molecular Imaging | 2016 | 143 |
40 | The Latest Developments in Imaging of Fibroblast Activation Protein | Journal of Nuclear Medicine | 2021 | 143 |
41 | Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study | Journal of Nuclear Medicine | 2018 | 140 |
42 | Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients | Journal of Nuclear Medicine | 2020 | 136 |
43 | Targeting of activated fibroblasts for imaging and therapy | EJNMMI Radiopharmacy and Chemistry | 2019 | 134 |
44 | Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA | European Urology | 2021 | 128 |
45 | Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 124 |
46 | Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study | Lancet Oncology, The | 2021 | 120 |
47 | Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers | European Journal of Nuclear Medicine and Molecular Imaging | 2020 | 119 |
48 | 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging | Theranostics | 2020 | 117 |
49 | Impaired uptake of conjugated bile acids and hepatitis b virus pres1‐binding in na+‐taurocholate cotransporting polypeptide knockout mice | Hepatology | 2015 | 116 |
50 | Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2018 | 116 |